Clinical Trial Update: NEPA in Patients With HER2-positive or HER2-low Advanced Breast Cancer Treated With T-DXd

View source ↗

Summary

Clinical trial update indicates NEPA is being studied for patients with HER2-positive or HER2-low advanced breast cancer who are treated with trastuzumab deruxt…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Breast Cancer Low

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)
• NEPA (netupitant/palonosetron)

Snippet

Sponsor: Yeon Hee Park | Conditions: Patients With HER2-positive Advanced Breast Cancer Treated With T-DXd, Patients With HER2-low Advanced Breast Cancer Treated With T-DXd | Status: ENROLLING_BY_INVITATION